Retina

Serena Salvatore, MD, discusses the retinal laser training gap, persistent laser myths, simulation and practical advice for safer laser at EURETINA 2026.

Ester Carreño, MD, PhD, explains how to tell retinitis pigmentosa from uveitis and why genetic confirmation now matters more.

Women’s systemic and ocular health associated with pregnancy is a focus at EURETINA 2026 in Vienna.

Three EURETINA 2026 e-posters examine OCT/OCTA biomarkers and real-world switching to faricimab or aflibercept 8 mg in nAMD.

Japan's filing covers IRDs broadly, supported by RESTORE and open-label Stargardt data.

Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.

An industry symposium on intravitreal 4D-150 and a course on subretinal delivery lead gene therapy content at EURETINA 2026, alongside IRD courses and trial readouts.

Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.

Study found anti-VEGF therapy was linked to kidney function decline in patients with diabetic retinopathy or retinal vein occlusion.

Non-invasive electrical stimulation delivered through closed eyelids improved retinal structure and photoreceptor function.

Jesse L. Berry, MD, discusses prospective data on aqueous humor liquid biopsy in retinoblastoma and explains how molecular markers from the aqueous are beginning to guide recurrence risk, treatment intensity, and the workup of otherwise diagnostically inaccessible intraocular lesions.

At Retina Society 2026, Eileen Hwang, MD, PhD, discusses a meta-analysis finding a 1.78 times higher retinal detachment rate in COL2A1 vs COL11A1 Stickler syndrome and the case for prophylactic laser.

At Retina Society 2026, Nimesh Patel, MD, discusses how stage 2 ROP before 34 weeks raises the treatment rate and why he urges early referral and a risk-tailored approach to care.

Charles Wykoff, MD, PhD, reviews LUGANO safety and treatment burden data, including a 42% injection reduction with vorolanib insert vs aflibercept, despite a missed primary end point.

Subretinal deposits are linked to worse surgical risks in patients with severe aortic stenosis and reduced systemic blood flow.

Chhablani reports revakinagene taroretcel-lwey slowed cavitation volume growth and preserved photoreceptor structure in MacTel type 2.

One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.

Christine Kay, MD, discusses 4-year REMAIN data showing durable visual acuity gains with MCO-010, a mutation-agnostic intravitreal optogenetic therapy for advanced retinitis pigmentosa.

Remigromig met its BRUNELLO primary end point in DME, with higher PDR and vitreous hemorrhage rates than ranibizumab.

Study found anti-VEGF therapy was linked to kidney function decline in patients with diabetic retinopathy or retinal vein occlusion.

Anat Loewenstein, MD, previews EURETINA 2026 Vienna: the Innovation Spotlight, 17 sessions, symposia, and more.

RCA's first State of Retina Care report surveys 115+ affiliated specialists on access, practice pressures, and clinical research.

The FDA has accepted Nanoscope's BLA for sonpiretigene isteparvovec in retinitis pigmentosa, backed by RESTORE and REMAIN trial data.

Alessandro Arrigo, MD, previews an ESCRS 2026 presentation on a patent-pending method that adapts blue light autofluorescence confocal imaging to grade cataracts objectively. The approach yielded reproducible numeric indices that correlated with both expert LOCS III scores and measurable loss of retinal image quality.

After four years and 500+ office-based procedures, Johnathan Feistmann, MD, shares how the model shortened time to surgery for fovea-threatening cases while reshaping patient experience and practice workflow.